This study will be restricted to all original articles of healthy adults (people not suffering from any diseases). We will exclude minors, pregnant women, those planning a pregnancy, and lactating women.
Conditions
Interventions
None listed
Sponsors
KAGOME CO., LTD.
Review Team Professor Hiroharu Kamioka, Department of Ecological Symbiotic Science, Tokyo University of Agriculture Ms. Mari Makishi, NARASHINO Media Center for Research &
Education, Media Net Center, TOHO University. Mr. Takuro Inoue, Innovation Division, KAGOME CO., LTD. Mr. Kazutaka Yoshida, Innovation Division, KAGOME CO., LTD. Ms. Erika Sasaki, Innovation Division, KAGOME CO., LTD.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (Study design) We will include randomized controlled trials (RCT), randomized crossover trials, quasi randomized controlled trials (qRCT), quasi randomized crossover trials, non-randomized controlled trials (nonRCT), non-randomized crossover trials, cohort studies, and case-control studies. We will include scientific papers and reports which give us enough research details. (PICO) Participant: We will include people not suffering from any diseases. We will exclude minors, pregnant women, those planning a pregnancy, and lactating women. Intervention: We define oral intake of test foods containing lycopene as intervention. Comparison: We define oral intake of test foods not containing lycopene, oral intake of test foods containing lower level of lycopene than intervention, and no any intervention, as control. Outcome measurement: We will evaluate blood HDL-C and LDL-C levels as primary outcomes. We will evaluate LDL/HDL ratio as secondary outcome. (PECO) Participant: We will include people not suffering from any diseases. We will exclude minors, pregnant women, those planning a pregnancy, and lactating women. Exposure: We define oral intake of foods containing lycopene as exposure. Comparison: We define eating no food containing lycopene as non-exposure. If subgroup analysis of lycopene intake amount has been conducted in a study, we define the least intake group as a non-exposure group. Outcome measurement: We will evaluate blood HDL-C and LDL-C levels as primary outcomes. We will evaluate LDL/HDL ratio as secondary outcome. (Language) Eligibility is not restricted by language.
Exclusion criteria
Exclusion criteria: We will exclude cross-sectional studies because it will be difficult to interpret causal relationships between exposure and outcome. We will also exclude proceedings and unpublished studies which don't give us enough research details. However, we will include unpublished studies if registered in the protocol registration system.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will evaluate the effects of lycopene intake on blood HDL-C and LDL-C levels. | — |
Secondary
| Measure | Time frame |
|---|---|
| We will evaluate the effect of lycopene intake on LDL/HDL ratio. | — |
Countries
Japan
Contacts
Public ContactKoichi Aizawa
KAGOME CO., LTD. Innovation Division
Outcome results
None listed